Tenax Therapeutics Inc (TENX NASDAQ) stock market data APIs
$6.3009
0.19(3%)
as of September 17, 2025
Try our APIs with
free plan!
Tenax Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
Prev. Close
6.3009
Open
6.4954
High
6.5552
Low
6.0916
52 wk Range
3.25-7.89
Market Cap
28 744 K
P/E Ratio
2.1429
Shares Outstanding
4 563 K
EPS
-0.27
Beta
1.443
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tenax Therapeutics Inc data using free add-ons & libraries
Get Tenax Therapeutics Inc Fundamental Data
Tenax Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -19 486 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-13
- EPS/Forecast: -0.21
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tenax Therapeutics Inc News
New
Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF
Provides Patent Protection in Europe Through at Least December 2040 Further IP Protection for TNX-103 (Oral Levosimendan) and Other Drug Formulations, and its Active Metabolites, in PH-HFpEF Also Pr...
Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025
CHAPEL HILL, N.C., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company usin...
Tenax Posts Wider Loss in Fiscal Q2
Key Points Net loss totaled $10.85 million for Q2 2025, compared to $3.6 million in Q2 2024. Operating expenses more than tripled in Q2 2025 versus Q2 2024, driven by higher R&D and G&A costs, includ...
Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2,...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
